Cargando…

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives

Long acting injectables antipsychotics (LAIs) preparations were introduced for the first time in 1960s for management of schizophrenia. Over the years, many LAIs have been introduced. A recent meta-analysis of prospective and retrospective studies evaluating the effectiveness of LAIs vis-à-vis oral...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Symposium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129605/ http://dx.doi.org/10.4103/0019-5545.341900

Ejemplares similares

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
por: Marpepa, B., et al.
Publicado: (2022)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia
por: Salvi, Virginio, et al.
Publicado: (2022)

Chlamydial eye infections: Current perspectives
por: Satpathy, Gita, et al.
Publicado: (2017)

Lais /
por: France, Marie de
Publicado: (1994)

Challenges in Treating Schizophrenia with LAIs – Analysis of Own Results
por: Todorov, A. A., et al.
Publicado: (2023)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

Medical negligence liability under the consumer protection act: A review of judicial perspective
por: Joga Rao, S. V.
Publicado: (2009)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
por: McKee, Kyle A., et al.
Publicado: (2021)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
por: Lin, Yao-Yu, et al.
Publicado: (2023)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Drug attitude inventory is relevant to LAI treatment persistence in schizophrenia: Preliminary results
por: D’Anna, G., et al.
Publicado: (2021)

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing
por: Piacentino, D., et al.
Publicado: (2022)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
por: Prajapati, Asta R, et al.
Publicado: (2016)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Medical radiation countermeasures for nuclear and radiological emergencies: Current status and future perspectives
por: Arora, Rajesh, et al.
Publicado: (2010)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

INFECTIONS, INFLAMMATORY MARKERS AND SCHIZOPHRENIA
por: Dickerson, Faith, et al.
Publicado: (2014)

Impact of Schizophrenia on Caregivers: Indian Research
Publicado: (2022)

Current Treatment Strategies in Pediatric Alopecia Areata
por: Wang, Etienne, et al.
Publicado: (2012)

Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration
por: Gopal, Lekha, et al.
Publicado: (2007)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

A Current Perspective on Leishmaniasis
por: Clem, Angela
Publicado: (2010)

Current Treatment Strategies: Collagen Vascular Diseases in Children
por: Palit, Aparna, et al.
Publicado: (2012)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hdr4vqsqls3p3kivphjecg0ups